Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome

Inclusion Criteria: * A biopsy compatible with the diagnosis of MF and sezary syndrome with a CD4 positive phenotype within 6 months of study entry * Refractory to or intolerant to at least two prior therapies, one being Targretin® (or combinations hereof). * Signed informed consent Exclusion Criteria: * Prior treatment with Total Skin Electron Beam (TSEB) therapy within six months * Prior treatment with Campath (alemtuzumab) * Prior treatment with more than three regimens of single agent chemotherapy * Prior treatment with pentostatin within 6 months * Treatment within 4 weeks prior to visit 2 with topical Targretin®, skin directed therapies or systemic anticancer therapies, such as, but not limited to: Targretin® , UV-light therapy, local Electron Beam Therapy (EBT), extracorporal photo chemotherapy, methotrexate, bleomycin, cyclophosphamide, combination chemotherapy, oral retinoids, systemic glucocorticosteroids , carmustine, nitrogen mustard, systemic vitamin A or etretinate * Treatment with topical glucocorticosteroids within 2 weeks prior to visit 2 * Unwillingness or inability to avoid prolonged exposure to the sun or UV light sufficient to produce a mild erythema or thought by the investigator to likely modify the patient's disease * Concurrent or previous malignancies within the past five years except adequately treated in situ carcinoma of the uterine cervix or basal or squamous cell skin carcinoma * Significant concurrent, uncontrolled, or active medical condition including, but not limited to renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, cerebral or psychiatric disease * Known or suspected positive serology for HIV * Known or suspected positive serology for hepatitis B or C * Patients who are currently participating in any other trials or having received treatment with any experimental agent within 4 weeks prior to visit 1 (screening) * Prior treatment with anti-CD4 monoclonal antibodies * Breast feeding women or women with a positive pregnancy test at Visit 1 * Women of childbearing potential not willing to use either hormonal birth control, an intrauterine device or double-barrier method for the entire study period